Apimeds Pharmaceuticals US (APUS) Cash & Current Investments (2023 - 2025)

Apimeds Pharmaceuticals US has reported Cash & Current Investments for 3 years, with the latest figure at $3.6 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Current Investments rose 105157.74% year-over-year to $3.6 million; the trailing twelve-month figure through Dec 2025 stood at $3.6 million (up 105157.74% YoY), and the FY2025 full-year result was $3.6 million, up 105157.74% from the prior year.
• Cash & Current Investments for Q4 2025 stood at $3.6 million, down from $7.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $8.7 million in Q2 2025, with the low at $3455.0 in Q4 2024.
• Historically, Cash & Current Investments has averaged $3.3 million across 3 years, with a median of $2.0 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Current Investments tumbled 99.16% — and 2025, when it surged 105157.74%.
• Apimeds Pharmaceuticals US's Cash & Current Investments stood at $410481.0 in 2023, then plunged by 99.16% to $3455.0 in 2024, then surged by 105157.74% to $3.6 million in 2025.
• The last three Cash & Current Investments figures came in at $3.6 million (Q4 2025), $7.0 million (Q3 2025), and $8.7 million (Q2 2025), per Business Quant data.